A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC
This is a phase II study. All patients are stage IIIB/C or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 in combination with chemotherapy in patients with NSCLC.
NSCLC
DRUG: AK112|DRUG: Pemetrexed|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Docetaxel
ORR, ORR is the proportion of subjects with CR or PR , based on RECIST v1.1., Up to approximately 2 years
PFS, PFS is defined as the time from the date of first dosing till the first documentation of disease progression (per RECIST v1.1 criteria) assessed by the investigator or death due to any cause (whichever occurs first)., Up to approximately 2 years|OS, OS is the time from the date of randomization or first dosing date to death due to any cause., Up to approximately 2 years|Disease control rate, DCR is defined as the proportion of subjects with CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for â‰¥8 weeks) based on RECIST Version 1.1, Up to approximately 2 years
This is a phase II study. All patients are stage IIIB/C or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 in combination with chemotherapy in patients with NSCLC.